Who commented on Requests that the FDA require a new warning concerning the risk of esophageal cancer for all over-the-counter (“OTC”) drug products that are labeled to relieve or prevent heartburn associated with reflux disease, acid indigestion and sour stomach?

Question

Who commented on Requests  that the FDA require a new warning concerning the risk of esophageal cancer for all over-the-counter (“OTC”) drug products that are labeled to relieve or prevent heartburn associated with reflux disease, acid indigestion and sour stomach?

Accepted Answer

1 organizations filed 1 public comments on Requests  that the FDA require a new warning concerning the risk of esophageal cancer for all over-the-counter (“OTC”) drug products that are labeled to relieve or prevent heartburn associated with reflux disease, acid indigestion and sour stomach (FDA-2017-P-2733) on regulations.gov.

Requests that the FDA require a new warning concerning the risk of esophageal cancer for all over-the-counter (“OTC”) drug products that are labeled to relieve or prevent heartburn associated with reflux disease, acid indigestion and sour stomach

Abstract

Commenters (1)